Hmdb loader
Record Information
Version5.0
StatusDetected but not Quantified
Creation Date2021-09-11 21:57:29 UTC
Update Date2021-09-26 23:16:55 UTC
HMDB IDHMDB0259400
Secondary Accession NumbersNone
Metabolite Identification
Common NameUlixertinib
Description4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-N-[1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide belongs to the class of organic compounds known as 2-heteroaryl carboxamides. 2-heteroaryl carboxamides are compounds containing a heteroaromatic ring that carries a carboxamide group. Based on a literature review very few articles have been published on 4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-N-[1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide. This compound has been identified in human blood as reported by (PMID: 31557052 ). Ulixertinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Ulixertinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources.
Structure
Thumb
SynonymsNot Available
Chemical FormulaC21H22Cl2N4O2
Average Molecular Weight433.33
Monoisotopic Molecular Weight432.1119814
IUPAC Name4-{5-chloro-2-[(propan-2-yl)amino]pyridin-4-yl}-N-[1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
Traditional Name4-[5-chloro-2-(isopropylamino)pyridin-4-yl]-N-[1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide
CAS Registry NumberNot Available
SMILES
CC(C)NC1=NC=C(Cl)C(=C1)C1=CNC(=C1)C(=O)NC(CO)C1=CC(Cl)=CC=C1
InChI Identifier
InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)
InChI KeyKSERXGMCDHOLSS-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as 2-heteroaryl carboxamides. 2-Heteroaryl carboxamides are compounds containing a heteroaromatic ring that carries a carboxamide group.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct Parent2-heteroaryl carboxamides
Alternative Parents
Substituents
  • 2-heteroaryl carboxamide
  • Pyrrole-2-carboxamide
  • Pyrrole-2-carboxylic acid or derivatives
  • Aminopyridine
  • Chlorobenzene
  • Halobenzene
  • Secondary aliphatic/aromatic amine
  • Imidolactam
  • Benzenoid
  • Substituted pyrrole
  • Aryl chloride
  • Pyridine
  • Aryl halide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Pyrrole
  • Secondary carboxylic acid amide
  • Amino acid or derivatives
  • Organoheterocyclic compound
  • Secondary amine
  • Azacycle
  • Organic oxide
  • Organochloride
  • Organohalogen compound
  • Organonitrogen compound
  • Amine
  • Organooxygen compound
  • Primary alcohol
  • Organic nitrogen compound
  • Organic oxygen compound
  • Alcohol
  • Hydrocarbon derivative
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
logP4.09ALOGPS
logP3.62ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)14.45ChemAxon
pKa (Strongest Basic)4.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.04 ŲChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.51 m³·mol⁻¹ChemAxon
Polarizability45.2 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+202.86930932474
DeepCCS[M-H]-200.51130932474
DeepCCS[M-2H]-233.83130932474
DeepCCS[M+Na]+209.05930932474

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
UlixertinibCC(C)NC1=NC=C(Cl)C(=C1)C1=CNC(=C1)C(=O)NC(CO)C1=CC(Cl)=CC=C14814.1Standard polar33892256
UlixertinibCC(C)NC1=NC=C(Cl)C(=C1)C1=CNC(=C1)C(=O)NC(CO)C1=CC(Cl)=CC=C13519.6Standard non polar33892256
UlixertinibCC(C)NC1=NC=C(Cl)C(=C1)C1=CNC(=C1)C(=O)NC(CO)C1=CC(Cl)=CC=C13808.1Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Ulixertinib,2TMS,isomer #1CC(C)N(C1=CC(C2=C[NH]C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C3430.8Semi standard non polar33892256
Ulixertinib,2TMS,isomer #1CC(C)N(C1=CC(C2=C[NH]C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C3424.4Standard non polar33892256
Ulixertinib,2TMS,isomer #1CC(C)N(C1=CC(C2=C[NH]C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C4639.5Standard polar33892256
Ulixertinib,2TMS,isomer #2CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N13579.9Semi standard non polar33892256
Ulixertinib,2TMS,isomer #2CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N13460.0Standard non polar33892256
Ulixertinib,2TMS,isomer #2CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N14476.4Standard polar33892256
Ulixertinib,2TMS,isomer #3CC(C)NC1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N13489.2Semi standard non polar33892256
Ulixertinib,2TMS,isomer #3CC(C)NC1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N13453.2Standard non polar33892256
Ulixertinib,2TMS,isomer #3CC(C)NC1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N14424.1Standard polar33892256
Ulixertinib,2TMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C3517.0Semi standard non polar33892256
Ulixertinib,2TMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C3453.9Standard non polar33892256
Ulixertinib,2TMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C4500.6Standard polar33892256
Ulixertinib,2TMS,isomer #5CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3393.5Semi standard non polar33892256
Ulixertinib,2TMS,isomer #5CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3416.6Standard non polar33892256
Ulixertinib,2TMS,isomer #5CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C4430.9Standard polar33892256
Ulixertinib,2TMS,isomer #6CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N13545.3Semi standard non polar33892256
Ulixertinib,2TMS,isomer #6CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N13356.0Standard non polar33892256
Ulixertinib,2TMS,isomer #6CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N14443.9Standard polar33892256
Ulixertinib,3TMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C3483.7Semi standard non polar33892256
Ulixertinib,3TMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C3484.6Standard non polar33892256
Ulixertinib,3TMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)NC(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C4182.2Standard polar33892256
Ulixertinib,3TMS,isomer #2CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3408.8Semi standard non polar33892256
Ulixertinib,3TMS,isomer #2CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3461.6Standard non polar33892256
Ulixertinib,3TMS,isomer #2CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C4111.9Standard polar33892256
Ulixertinib,3TMS,isomer #3CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N13525.8Semi standard non polar33892256
Ulixertinib,3TMS,isomer #3CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N13410.7Standard non polar33892256
Ulixertinib,3TMS,isomer #3CC(C)NC1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N14150.5Standard polar33892256
Ulixertinib,3TMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3448.5Semi standard non polar33892256
Ulixertinib,3TMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3382.7Standard non polar33892256
Ulixertinib,3TMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C4164.4Standard polar33892256
Ulixertinib,4TMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3495.6Semi standard non polar33892256
Ulixertinib,4TMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3425.3Standard non polar33892256
Ulixertinib,4TMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C3910.3Standard polar33892256
Ulixertinib,2TBDMS,isomer #1CC(C)N(C1=CC(C2=C[NH]C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3845.5Semi standard non polar33892256
Ulixertinib,2TBDMS,isomer #1CC(C)N(C1=CC(C2=C[NH]C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3868.0Standard non polar33892256
Ulixertinib,2TBDMS,isomer #1CC(C)N(C1=CC(C2=C[NH]C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4667.4Standard polar33892256
Ulixertinib,2TBDMS,isomer #2CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N13974.6Semi standard non polar33892256
Ulixertinib,2TBDMS,isomer #2CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N13837.0Standard non polar33892256
Ulixertinib,2TBDMS,isomer #2CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N14512.7Standard polar33892256
Ulixertinib,2TBDMS,isomer #3CC(C)NC1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N13873.4Semi standard non polar33892256
Ulixertinib,2TBDMS,isomer #3CC(C)NC1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N13881.9Standard non polar33892256
Ulixertinib,2TBDMS,isomer #3CC(C)NC1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N14478.6Standard polar33892256
Ulixertinib,2TBDMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3935.2Semi standard non polar33892256
Ulixertinib,2TBDMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3873.6Standard non polar33892256
Ulixertinib,2TBDMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4506.7Standard polar33892256
Ulixertinib,2TBDMS,isomer #5CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3795.5Semi standard non polar33892256
Ulixertinib,2TBDMS,isomer #5CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3874.8Standard non polar33892256
Ulixertinib,2TBDMS,isomer #5CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4457.0Standard polar33892256
Ulixertinib,2TBDMS,isomer #6CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N13946.8Semi standard non polar33892256
Ulixertinib,2TBDMS,isomer #6CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N13774.3Standard non polar33892256
Ulixertinib,2TBDMS,isomer #6CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N14472.6Standard polar33892256
Ulixertinib,3TBDMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4079.8Semi standard non polar33892256
Ulixertinib,3TBDMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4093.8Standard non polar33892256
Ulixertinib,3TBDMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)NC(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4306.6Standard polar33892256
Ulixertinib,3TBDMS,isomer #2CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C3953.8Semi standard non polar33892256
Ulixertinib,3TBDMS,isomer #2CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4122.9Standard non polar33892256
Ulixertinib,3TBDMS,isomer #2CC(C)N(C1=CC(C2=C[NH]C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4237.7Standard polar33892256
Ulixertinib,3TBDMS,isomer #3CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N14105.7Semi standard non polar33892256
Ulixertinib,3TBDMS,isomer #3CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N14028.0Standard non polar33892256
Ulixertinib,3TBDMS,isomer #3CC(C)NC1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N14285.0Standard polar33892256
Ulixertinib,3TBDMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4047.2Semi standard non polar33892256
Ulixertinib,3TBDMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4030.0Standard non polar33892256
Ulixertinib,3TBDMS,isomer #4CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4269.6Standard polar33892256
Ulixertinib,4TBDMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4236.3Semi standard non polar33892256
Ulixertinib,4TBDMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4248.4Standard non polar33892256
Ulixertinib,4TBDMS,isomer #1CC(C)N(C1=CC(C2=CN([Si](C)(C)C(C)(C)C)C(C(=O)N(C(CO[Si](C)(C)C(C)(C)C)C3=CC=CC(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2)=C(Cl)C=N1)[Si](C)(C)C(C)(C)C4124.5Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a4i-0942400000-5e6b38b2c321e135a1a12021-09-23Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TMS_1_1) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TMS_1_3) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TMS_1_4) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TBDMS_1_1) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TBDMS_1_2) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TBDMS_1_3) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Ulixertinib GC-MS (TBDMS_1_4) - 70eV, PositiveNot Available2021-11-05Wishart LabView Spectrum
Biological Properties
Cellular LocationsNot Available
Biospecimen Locations
  • Blood
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodDetected but not QuantifiedNot QuantifiedNot SpecifiedNot SpecifiedNormal details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID35143273
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound58641927
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Barupal DK, Fiehn O: Generating the Blood Exposome Database Using a Comprehensive Text Mining and Database Fusion Approach. Environ Health Perspect. 2019 Sep;127(9):97008. doi: 10.1289/EHP4713. Epub 2019 Sep 26. [PubMed:31557052 ]